Latest News
-
Friday - January 27, 2012
Milestone for stacked insect-resistant, herbicide-tolerant cotton
Bayer CropScience’s TwinLink® cotton technology receives full authorization in the US » more
-
Friday - January 27, 2012
“Sustainability Yearbook 2012” listing globally top performers presented in Davos:
Bayer rated the most sustainable German company in its sector
One of just three chemical companies worldwide to receive Gold Class seal of quality from rating agency SAM » more
-
Friday - January 27, 2012
CEO Sandra Peterson at the 2012 World Economic Forum in Davos:
Bayer CropScience committed to the “New Vision for Agriculture” Initiative
Active role in global initiative to transform agriculture / Innovative, multi-stakeholder partnerships key to develop the agricultural sector » more
-
Friday - January 27, 2012
Bayer MaterialScience at UTECH 2012 in Maastricht:
Building blocks for efficient climate protection
Company develops sustainable polyurethane solutions for global megatrends » more
-
Friday - January 27, 2012
Not intended for U.S. and UK media - Indication extension for contrast medium
Bayer receives green light from EU authorities to use Gadovist® 1.0 in children aged two years and older » more
-
Tuesday - January 24, 2012
Bayer CropScience at the International Green Week, Berlin, Germany:
Bayer affirms commitment to safeguard food security through innovation and sustainable agriculture » more
-
Friday - January 20, 2012
Construction starts at Chempark Leverkusen:
Bayer MaterialScience builds multipurpose plant for coating raw materials
Total investment of roughly EUR 35 million / Efficient and flexible production of HDI and IPDI / Rising demand for high-performance polyurethane automotive coatings » more
-
Thursday - January 19, 2012
Bayer HealthCare Expands Research and Manufacturing Capabilities for Interventional Franchise » more
-
Wednesday - January 18, 2012
Not intended for UK and US Media - Stroke Prevention in Patients with Atrial Fibrillation:
Bayer’s Xarelto® Approved in Japan for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation » more
-
Wednesday - January 18, 2012
Not intended for U.S. and UK Media (LBA #385) - Results of pivotal Phase III study in patients with metastatic colorectal cancer:
Positive Phase III Data on Bayer’s Investigational Drug Regorafenib Show Significant Increase in Overall Survival
First presentation of data from CORRECT trial as “Late Breaking Abstract” at the 2012 Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI) » more
-
Monday - January 16, 2012
Innovative and sustainable logistic solutions for the future
Bayer MaterialScience and partners present concept for the last mile at imm » more
-
Monday - January 16, 2012
EUR 5 million investment in Chempark Dormagen
Bayer MaterialScience commissions new hydrogenation technical center
Pooling of research activities for the efficient production of MDI and TDI » more
-
Tuesday - January 10, 2012
Not intended for US Media: Gastrointestinal Cancers Symposium of the American Society of Clinical Oncology (ASCO-GI):
Phase III Data of Bayer’s Regorafenib in Patients with Metastatic Colorectal Cancer to be Presented as Late Breaking Oral Presentation at 2012 ASCO-GI Congress
Late breaking abstract (LBA #385) of Phase III CORRECT study results to be presented on January 21, 2012 » more
-
Tuesday - January 10, 2012
Bayer MaterialScience at Debau trade fair in Essen
Holistic building concepts for the housing industry
EcoCommercial Building Program offers sustainable and innovative building solutions » more
-
Monday - January 9, 2012
Bayer HealthCare to Share Lab Space with Start-Up Companies
Dedicated lab space-model at Bayer HealthCare U.S. Innovation Center to be called CoLaborator™ / Shared lab space will help promising life science companies get their start » more
-
Thursday - December 29, 2011
Not intended for U.S. and UK Media - Submission in New Indication:
Bayer’s Xarelto® (Rivaroxaban) Submitted for U.S. Marketing Authorisation to Reduce Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome » more
-
Thursday - December 22, 2011
Not intended for U.S. and UK media: Acute Coronary Syndrome (ACS):
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for Secondary Prevention after an Acute Coronary Syndrome
Submission based on positive results of ATLAS ACS 2-TIMI 51 study / Xarelto is the only new oral anticoagulant to demonstrate significant clinical benefit in this indication when used in combination with standard antiplatelet therapy » more
-
Tuesday - December 20, 2011
Not intended for U.S. and UK media: Clear commitment to innovation
Bayer: Four potential blockbusters in the Pharma pipeline
Good prospects for Xarelto™, VEGF Trap-Eye, Alpharadin and regorafenib / Market launches in the next 18 months planned / Research and development budget for 2012 approximately EUR 3 billion again » more
-
Tuesday - December 20, 2011
Chris Southwell participates in the world’s most famous triathlon:
Going to great lengths
Professional snowboarder and type 1 diabetic explores his limits at the Iron Man » more
-
Monday - December 19, 2011
For use outside the US and UK only
Bayer’s Xarelto® Approved in the EU for the Prevention of Stroke in Patients with AF and in the Treatment of DVT
In stroke prevention in AF, Xarelto is the only oral anticoagulant offering patients a once-daily, highly effective therapy without need for routine coagulation monitoring / For the treatment of DVT and the prevention of recurrent DVT and PE, Xarelto is the first oral anticoagulant to offer patients both efficacy and the convenience of a single-drug solution, without the need for injections or monitoring / Xarelto is now approved in the EU across three indications in the area of venous and arterial thromboembolism (VAT) » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Download Center - Selection
Bayer TV
